Pancreatic Cancer Research

ResearcherUniversity Medical Center Hamburg-EppendorfNo recent work listed

Yogesh Kumar Vashist

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2030-6712; OpenAlex author ID A5031059788. Sources: OpenAlex.

Their work

Papers
27 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2011: 4 papers · 2012: 2 papers · 2013: 1 paper · 2014: 4 papers · 2015: 3 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 5 papers

Papers 27

  1. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  2. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  3. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  4. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  5. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  6. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  7. Alignment of stroma fibers, microvessel density and immune cell populations determine overall survival in pancreatic cancer-An analysis of stromal morphology. Co-author DOI 10.1371/journal.pone.0234568↗
  8. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  9. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  10. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  11. Kidney Transplantation after Extended Multivisceral Resection for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2018/3757382↗
  12. HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer. Last author DOI 10.1007/s10495-016-1332-4↗
  13. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  14. Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry. Co-author DOI 10.1002/jso.23826↗
  15. Resection margin clearance in pancreatic cancer after implementation of the Leeds Pathology Protocol (LEEPP): clinically relevant or just academic? Co-author DOI 10.1007/s00268-014-2808-4↗
  16. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  17. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.001↗
  18. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.009↗
  19. The multifunctional growth factor midkine promotes proliferation and migration in pancreatic cancer. Co-author DOI 10.1158/1541-7786.mcr-13-0467↗
  20. Serum EpCAM expression in pancreatic cancer. Co-author PMID 25202052↗
  21. [S3-guideline exocrine pancreatic cancer]. Co-author DOI 10.1055/s-0033-1356220↗
  22. Disseminated tumor cells in pancreatic cancer-an independent prognosticator of disease progression and survival. Co-author DOI 10.1002/ijc.26439↗
  23. Losses at chromosome 4q are associated with poor survival in operable ductal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2011.11.001↗
  24. Heme oxygenase-1 germ line GTn promoter polymorphism is an independent prognosticator of tumor recurrence and survival in pancreatic cancer. Co-author DOI 10.1002/jso.21926↗
  25. Multivisceral resections in pancreatic cancer: identification of risk factors. Co-author DOI 10.1007/s00268-011-1263-8↗
  26. Bypass surgery versus intentionally incomplete resection in palliation of pancreatic cancer: is resection the lesser evil? Co-author DOI 10.1007/s11605-011-1469-y↗
  27. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-11-0036↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jakob Robert Izbicki · 14 shared papers, 2011–2018 · strength 0.57
  2. Maximilian Bockhorn · 9 shared papers, 2011–2015 · strength 0.33
  3. Ulrich Friedrich Wellner · 3 shared papers, 2017–2020 · strength 0.26
  4. Tobias Keck · 2 shared papers, 2018–2020 · strength 0.19
  5. Hryhoriy V. Lapshyn · 2 shared papers, 2018–2020 · strength 0.19
  6. Louisa Bolm · 2 shared papers, 2018–2020 · strength 0.19
  7. Michael Tachezy · 5 shared papers, 2011–2015 · strength 0.19
  8. Florian Gebauer · 5 shared papers, 2011–2015 · strength 0.18
  9. Cenap Güngör · 3 shared papers, 2011–2017 · strength 0.14
  10. Emre F. Yekebas · 4 shared papers, 2011–2015 · strength 0.13
  11. Matthias Reeh · 3 shared papers, 2011–2017 · strength 0.12
  12. Andreas M. Luebke · 2 shared papers, 2012–2018 · strength 0.11
  13. Ekaterina Petrova · 1 shared paper, 2020 · strength 0.11
  14. Steffen Deichmann · 1 shared paper, 2020 · strength 0.11
  15. Kim C. Honselmann · 1 shared paper, 2020 · strength 0.11
  16. Kai A. Bachmann · 2 shared papers, 2014–2015 · strength 0.09
  17. Faik Güntac Uzunoglu · 2 shared papers, 2014 · strength 0.07
  18. Tarik Ghadban · 1 shared paper, 2017 · strength 0.07
  19. Dirk Jan Gouma · 2 shared papers, 2014 · strength 0.06
  20. Werner Hartwig · 2 shared papers, 2014 · strength 0.06
  21. Christos Dervenis · 2 shared papers, 2014 · strength 0.06
  22. Helmut Frieß · 2 shared papers, 2014 · strength 0.06
  23. Charles M. Vollmer · 2 shared papers, 2014 · strength 0.06
  24. Clement W. Imrie · 2 shared papers, 2014 · strength 0.06
  25. Markus Wolfgang Büchler · 2 shared papers, 2014 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.